Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Home›Research›Companies

Companies

Loading
Home›
Research›
Companies›
Hibernaid
AddedFeb 17, 2024
UpdatedJun 18, 2026
Hibernaid

Hibernaid

Angel

Hibernaid: A private firm developing unique acute medical therapies for high-risk critical care patients.

HQ
Troy, NY, US
Founded
2011
Overview
Compare
Fundraising
Employees

Hibernaid is a private company focused on developing unique drugs for acute medical indications, specifically targeting high-risk critical care patient populations. Their mission is to innovate in the field of acute medical therapies, providing advanced solutions for critical care scenarios.

Hibernaid has made significant strides in the medical field, contributing to the advancement of acute care treatments. Their work has had a notable impact on improving outcomes for patients in critical conditions, positioning them as a key player in the healthcare industry.

Hibernaid - Similar Companies

Hiberna logo

Hiberna

hiberna.co.nz

HiberCell logo

HiberCell

hibercell.com

Baudax Bio logo

Baudax Bio

Velomedix logo

Velomedix

Advanced Biomedics logo

Advanced Biomedics

Intellimedix logo

Intellimedix

Emit logo

Emit

Inception IBD logo

Inception IBD

Piraeus Medical logo

Piraeus Medical

BiomedInnovations logo

BiomedInnovations

Kantum Pharma logo

Kantum Pharma

Equani logo

Equani

Ikaria logo

Ikaria

Critical Biologics logo

Critical Biologics

Intact Medical logo

Intact Medical

Hibernaid - Quick Facts

Who are Hibernaid's competitors?

Companies similar to Hibernaid include Hiberna, HiberCell, Baudax Bio and Velomedix.

When was Hibernaid founded?

Hibernaid was founded in 2011.

Where is Hibernaid's headquarters located?

Hibernaid's headquarters is located in Troy, NY, US.

When was Hibernaid's last funding round?

Hibernaid's most recent funding round was for $100k (USD) in December 2017.

How much has Hibernaid raised to-date?

As of Dec 22, 2017, Hibernaid has raised a total of $100k (USD).

How many employees does Hibernaid have?

Hibernaid has 5 employees as of Feb 5, 2024.

Hibernaid - Classification

Ownership
  • Private
Technology
  • Biotech
Geographic Exposure
  • United States
Revenue
  • Recurring
  • Software
Customer
  • Enterprise
Main Product
  • Medical Therapies
Tags
  • Healthtech
NAICS
  • 320000Manufacturing
  • 325400Pharmaceutical and Medicine Manufacturing
  • 325000Chemical Manufacturing
  • 325410Pharmaceutical and Medicine Manufacturing
  • 325412Pharmaceutical Preparation Manufacturing
SIC
  • 2800Chemicals And Allied Products
  • 2830Drugs
  • 2834Pharmaceutical Preparations
ISIC
  • 7210Research and experimental development on natural sciences and engineering
Show 15 more industry codes
NAICS
  • 540000Professional, Scientific, and Technical Services
  • 541714Research and Development in Biotechnology (except Nanobiotechnology)
  • 620000Health Care and Social Assistance
  • 541000Professional, Scientific, and Technical Services
  • 623000Nursing and Residential Care Facilities
  • 541700Scientific Research and Development Services
  • 541710Research and Development in the Physical, Engineering, and Life Sciences
  • 541715Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
SIC
  • 8733Noncommercial Research Organizations
  • 8000Health Services
  • 8700Engineering, Accounting, Research, Management, And Related Services
  • 8040Offices And Clinics Of Other Health Practitioners
  • 8730Research, Development, And Testing Services
  • 8049Offices And Clinics Of Health Practitioners, Not Elsewhere Classified
  • 8731Commercial Physical and Biological Research